Insmed Inc Cash Flow Conversion Efficiency
Insmed Inc cash flow conversion efficiency. Based on the latest financial reports, Insmed Inc (INSM) has a cash flow conversion efficiency ratio of -0.232x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-219.76 Million) by net assets ($945.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Insmed Inc (1999–2024)
Cash flow conversion efficiency of Insmed Inc from 1999 to 2024. This chart illustrates how Insmed Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Insmed Inc for real-time trading data and today's change.
Insmed Inc Cash Flow Conversion Ratio Explained
Insmed Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Insmed Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Insmed Inc ranked by their cash flow conversion efficiency. Also see INSM market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Citizens BancShares, Inc.
NASDAQ:FCNCA
|
0.048x |
|
NOVOZYMES A/S SPONS.ADR 1
F:NZM
|
0.015x |
|
Expeditors International of Washington, Inc.
NYSE:EXPD
|
0.084x |
|
Nan Ya Printed Circuit Board Corp
TW:8046
|
0.021x |
|
Hydro One Ltd
TO:H
|
0.068x |
|
Repsol S.A
F:REPA
|
0.036x |
|
Ningxia Baofeng Energy Group Co Ltd
SHG:600989
|
0.059x |
|
Hapag Lloyd AG
XETRA:HLAG
|
0.017x |
Annual Cash Flow Conversion Efficiency for Insmed Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Insmed Inc from 1999 to 2024. Review Insmed Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $285.38 Million | $-683.88 Million | -2.396x | -248.33% |
| 2023-12-31 | $-331.92 Million | $-536.25 Million | 1.616x | +135.48% |
| 2022-12-31 | $87.95 Million | $-400.44 Million | -4.553x | -414.41% |
| 2021-12-31 | $410.47 Million | $-363.30 Million | -0.885x | -11.32% |
| 2020-12-31 | $275.88 Million | $-219.35 Million | -0.795x | +17.00% |
| 2019-12-31 | $261.67 Million | $-250.65 Million | -0.958x | +22.67% |
| 2018-12-31 | $208.27 Million | $-257.98 Million | -1.239x | -180.20% |
| 2017-12-31 | $361.06 Million | $-159.62 Million | -0.442x | +53.45% |
| 2016-12-31 | $154.48 Million | $-146.71 Million | -0.950x | -193.95% |
| 2015-12-31 | $311.70 Million | $-100.70 Million | -0.323x | +6.60% |
| 2014-12-31 | $186.24 Million | $-64.42 Million | -0.346x | -6.23% |
| 2013-12-31 | $143.32 Million | $-46.66 Million | -0.326x | -26.91% |
| 2012-12-31 | $120.88 Million | $-31.01 Million | -0.257x | -14.04% |
| 2011-12-31 | $134.27 Million | $-30.20 Million | -0.225x | -461.80% |
| 2010-12-31 | $192.84 Million | $-7.72 Million | -0.040x | +54.94% |
| 2009-12-31 | $123.91 Million | $-11.01 Million | -0.089x | -102.09% |
| 2008-12-31 | $-2.82 Million | $-11.99 Million | 4.248x | +293.23% |
| 2007-12-31 | $11.49 Million | $-25.25 Million | -2.198x | +27.70% |
| 2006-12-31 | $13.88 Million | $-42.20 Million | -3.041x | -15.31% |
| 2005-12-31 | $10.53 Million | $-27.77 Million | -2.637x | +23.38% |
| 2004-12-31 | $7.24 Million | $-24.90 Million | -3.442x | -738.53% |
| 2003-12-31 | $26.22 Million | $-10.76 Million | -0.410x | +60.04% |
| 2002-12-31 | $23.45 Million | $-24.08 Million | -1.027x | -92.93% |
| 2001-12-31 | $59.70 Million | $-31.78 Million | -0.532x | -140.59% |
| 2000-12-31 | $96.78 Million | $-21.42 Million | -0.221x | +86.35% |
| 1999-12-31 | $4.46 Million | $-7.23 Million | -1.621x | -- |
About Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antiba… Read more